InvestmentJul 14, 2026, 08:02 AM
AEON Biopharma Prices Public Offering to Raise Up to $43.3M
AI Summary
AEON Biopharma announced the pricing of an underwritten public offering, aiming to raise up to approximately $43.3 million in gross proceeds. This includes $13.75 million from the initial offering and an additional $29.6 million if milestone warrants are fully exercised in cash. The offering consists of 42,688,606 shares or pre-funded warrants, each accompanied by two-year and five-year milestone warrants. Proceeds are intended for working capital and general corporate purposes, specifically for comparative analytical testing of ABP-450.
Key Highlights
- Public offering priced to raise up to $43.3 million in gross proceeds.
- Expected initial gross proceeds of approximately $13.75 million.
- Potential additional $29.6 million from full cash exercise of milestone warrants.
- Offering includes 42,688,606 shares of common stock or pre-funded warrants.
- Combined public offering price is $0.3221 per share/warrant unit.
- Proceeds to fund working capital and ABP-450 comparative analytical testing.
- Two-year milestone warrants expire based on ABP-450 regulatory milestone.
- Five-year milestone warrants expire based on ABP-450 clinical development milestone.
Price Impact
More from AEON